Buy the following for the SwingTrade Portofolio

2,500 SMDM at $0.26
7,500 SMDM at $0.30

Cliff technically asked how my portfolio did last year although he may have meant the SwingTrade Portfolio.

My portfolio returns are different than the SwingTrade Portfolio as my personal portfolio is much larger than the SwingTrade Portfolio. I hold more positions than the SwingTrade Portfolio and obviously in different quantities. Nevertheless, the SwingTrade Portfolio generally gives a decent indication of how my personal portfolio is performing. The statistics in the article were for my personal portfolio which has existed for a longer time.

I was down 2.5% last year.

My New Blog....



http://microcapclub.com/2016/03/cash-is-a-position/

My New Blog....



http://microcapclub.com/2016/03/cash-is-a-position/

VolitionRx Announces Proposed Public Offering of Common Stock

https://finance.yahoo.com/news/volitionrx-announces-proposed-public-offering-200100121.html

SCKT prints $3.25. Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee

SCKT prints $3.10!

SCKT is printing a fresh 52 week high as I type.

http://microcapclub.com/2016/03/keep-it-simple/

BIOYF bid is US$5.32. Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeee

SCKT is up $0.08 to $2.93. IMO it deserves to be a lot higher. Patience.

http://microcapclub.com/2016/02/no-pain-no-gain/

http://microcapclub.com/2016/02/no-pain-no-gain/

RX.V / BIOYF Great results by this growing company. Ignoring a one-time charge they made $0.07. They just continue to grow and grow. If you forced me to own one company and not sell it for 5 years it would be them.

https://finance.yahoo.com/news/biosyent-releases-q4-full-2015-130000280.html

BioSyent Releases Q4 and Full Year 2015 Results

https://finance.yahoo.com/news/biosyent-releases-q4-full-2015-130000280.html

RX.V / BIOYF had a great report that exceeded my expectations. I think it is a likely multi-bagger over the next few years. http://finance.yahoo.com/news/biosyent-releases-q4-full-2015-130000280.html

Disclosure: This is my largest holding by far.

ISBG has never been in the portfolio.

For Q4, the one analyst on BioSyent is expecting $3.6M in revenue and earnings of $0.05/share. A side note is that this analyst is not covering Biosyent anymore as his whole department was laid off.

I think that is a reasonable guess as a starting point. Pharma sales in Q3 were $4.068M but included a large order of $627K which will not repeat. Insecticide Sales in Q4 is generally around $40-50K. So, $3.6M shows a slight bit of growth ignoring that large order.

That is short term.

Longer term I expect growth for many years. They should grow 20-25% each year. However, they also have a large cash pile. When the right deal comes, I suspect they will deploy that cash and it will cause a large bump in revenue and earnings for that year.

There was recently a nice conference call with BioSyent on MicroCapClub that gave insight into the longer term strategy.

I expect BioSyent to be a multi-bagger over several years.

RX.V / BIOYF reports next week....

https://finance.yahoo.com/news/biosyent-schedules-fourth-quarter-2015-224539413.html

First…Dominate a Small Market http://microcapclub.com/2016/02/firstdominate-a-small-market/

I like and own WFCF. The thesis is simple, there is an increasing demand for transparency in food to understand what is in it and where it comes from. Also, WFCF has a nice moat. This article helps to understand the value of a moat. http://microcapclub.com/2015/11/the-vision-to-see-economic-moats/

Look again. :)

Buy 1000 shares of OML.V/OLNCF for the SwingTrade Portfolio for $1.1401.

IZEA to Begin Trading on NASDAQ Capital Market on Friday, February 26, 2016

https://finance.yahoo.com/news/izea-begin-trading-nasdaq-capital-130000114.html

SCKT prints $2.96!

agreed

Buy 500 shares of SCKT at $2.80 for the SwingTrade Portfolio.

SCKT - Kaboom!

SCKT reports Q4 EPS of $0.16/share!

http://www.otcmarkets.com/stock/SCKT/news?id=125596

SCKT reports Q4 EPS of $0.16/share!

http://www.otcmarkets.com/stock/SCKT/news?id=125596

Fiscal Q2 (December 2015) EPS for FDVF was $0.012/share. It is quite undervalued.

http://www.otcmarkets.com/financialReportViewer?symbol=FDVF&id=150493

Yes. http://microcapclub.com/summit/

First…Dominate a Small Market http://microcapclub.com/2016/02/firstdominate-a-small-market/

First…Dominate a Small Market http://microcapclub.com/2016/02/firstdominate-a-small-market/

My average cost this time around (since early last year) is a little bit higher than the current price. So, yes, I think current prices are a good entry point.

Please do your own DD, however.

It is my largest holding.

I like investments I can illustrate with a crayon. For example, BioSyent - RX.V / BIOYF

I like investments I can illustrate with a crayon. For example, BioSyent - RX.V / BIOYF

I've been talking about OML.V for quite a while here although I don't own it presently.